These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11745208)

  • 1. Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors.
    Grzybicki DM; Liu Y; Moore SA; Brown HG; Silverman JF; D'Amico F; Raab SS
    Cancer; 2001 Nov; 92(10):2720-6. PubMed ID: 11745208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
    Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification.
    Nielsen LAG; Bangsø JA; Lindahl KH; Dahlrot RH; Hjelmborg JVB; Hansen S; Kristensen BW
    Diagn Pathol; 2018 Jun; 13(1):38. PubMed ID: 29885671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.
    Heesters MA; Koudstaal J; Go KG; Molenaar WM
    J Neurooncol; 1999; 44(3):255-66. PubMed ID: 10720205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study.
    Rodríguez-Pereira C; Suárez-Peñaranda JM; Vázquez-Salvado M; Sobrido MJ; Abraldes M; Barros F; Forteza J
    J Neurosurg Sci; 2000 Dec; 44(4):203-9; discussion 209-10. PubMed ID: 11327289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
    Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
    Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interobserver variability in determining MIB-1 labeling indices in oligodendrogliomas.
    Prayson RA; Castilla EA; Hembury TA; Liu W; Noga CM; Prok AL
    Ann Diagn Pathol; 2003 Feb; 7(1):9-13. PubMed ID: 12616468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods.
    Hsu CY; Ho DM; Yang CF; Chiang H
    Mod Pathol; 2003 Sep; 16(9):951-7. PubMed ID: 13679460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children.
    Czech T; Slavc I; Aichholzer M; Haberler C; Dietrich W; Dieckmann K; Koos W; Budka H
    J Neurooncol; 1999 Apr; 42(2):143-50. PubMed ID: 10421072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIB-1 counting methods in meningiomas and agreement among pathologists.
    Rezanko T; Akkalp AK; Tunakan M; Sari AA
    Anal Quant Cytol Histol; 2008 Feb; 30(1):47-52. PubMed ID: 18459587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases.
    Ho DM; Wong TT; Hsu CY; Ting LT; Chiang H
    Cancer; 1998 Jun; 82(12):2459-66. PubMed ID: 9635540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
    Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
    Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors.
    Ralte AM; Sharma MC; Karak AK; Mehta VS; Sarkar C
    Pathol Oncol Res; 2001; 7(4):267-78. PubMed ID: 11882906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of prognostic markers in brain tumors.
    Grzybicki DM; Moore SA
    Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas.
    Hsu DW; Louis DN; Efird JT; Hedley-Whyte ET
    J Neuropathol Exp Neurol; 1997 Aug; 56(8):857-65. PubMed ID: 9258255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.
    Johannessen AL; Torp SH
    Pathol Oncol Res; 2006; 12(3):143-7. PubMed ID: 16998593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular proliferation in pilocytic and diffuse astrocytomas.
    Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
    J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas.
    Coons SW; Johnson PC; Pearl DK
    Neurosurgery; 1997 Oct; 41(4):878-84; discussion 884-5. PubMed ID: 9316050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility and characteristics of MIB-1 labeling index as a proliferative activity marker in childhood low-grade glioma: a retrospective observational study.
    Gorodezki D; Zipfel J; Bevot A; Nägele T; Ebinger M; Schuhmann MU; Schittenhelm J
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):178. PubMed ID: 38580878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central neurocytoma: histologic atypia, proliferation potential, and clinical outcome.
    Mackenzie IR
    Cancer; 1999 Apr; 85(7):1606-10. PubMed ID: 10193953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.